Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?

Novo Nordisk has sharply cut out‑of‑pocket prices for its GLP‑1 drugs—reducing Ozempic and Wegovy from $499 to $349 per month for existing self‑pay patients and offering first‑time patients $199 for their first two doses—to blunt competitive pressure from Eli Lilly’s tirzepatide drugs (Mounjaro, Zepbound), low‑cost compounded semaglutide sold by telehealth firms like Hims & Hers, and pricing initiatives such as TrumpRx after its shares fell roughly two‑thirds over 18 months and management changed. The new pricing brings FDA‑approved products nearer parity with rivals (and with compounder price points around $199/month), a tactical move given limited regulatory action against compounded drugs. Novo is also gearing up for a potential commercial lift from an FDA decision on a Wegovy pill by year‑end and expanded supply, which could help it reclaim share in what analysts see as a potential ~$150 billion obesity drug market by 2035, albeit at the expense of near‑term margin compression.

Analysis

Novo Nordisk has implemented a material out-of-pocket price cut for self-paying patients, reducing Ozempic and Wegovy from $499 to $349 per month and offering first-time patients $199 for their first two doses (excluding the 2 mg Ozempic dose), a tactical response after shares lost roughly two-thirds of value over the past 18 months and a CEO change earlier this year. The move narrows price gaps versus Eli Lilly’s tirzepatide products (Mounjaro, Zepbound) and the $199/month compounded semaglutide available from telehealth providers such as Hims & Hers and platforms like TrumpRx, addressing both competitive and political pressure on drug pricing. Regulators have not removed compounded semaglutide from the market and enforcement uncertainty means price competition is the most direct lever; Lilly’s revenue growth has outpaced Novo’s over the past year, underscoring the competitive urgency. Novo Nordisk is also positioning for a potential commercial catalyst: an FDA decision on a Wegovy pill by year-end and an emphasized supply build, which could expand addressable demand but likely compress near-term margins as lower prices dilute unit economics.

Key Decisions for Investors

• Consider accumulating or adding to NVO selectively if early post-price-cut volume and channel data indicate share recovery, while sizing positions conservatively to allow for near-term margin compression
• Monitor LLY as a primary competitior—its faster revenue growth implies it may retain pricing power; consider relative reallocation between NVO and LLY contingent on upcoming sales cadence and market-share data
• Avoid speculative exposure to telehealth compounders such as HIMS until regulatory enforcement clarity emerges, and consider hedging NVO exposure against worse-than-expected margin deterioration or slower-than-expected uptake of the Wegovy pill